Journal article
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
Drugs of today (Barcelona, Spain : 1998), Vol.55(11), pp.683-693
11/01/2019
DOI: 10.1358/dot.2019.55.11.3035584
PMID: 31840683
Abstract
BRAF V600E mutations are associated with 8-10% of metastatic colorectal cancers (mCRC) and carry a poor prognosis with limited therapeutic options. In contrast to metastatic melanoma, BRAF inhibition alone or in combination with mitogen-activated protein kinase kinase (MEK) inhibitors has shown little utility in the treatment of BRAF V600E-mutant mCRC. This is secondary to upstream activation of the epidermal growth factor receptor (EGFR) pathway and other escape mechanisms. Combining RAF and MEK inhibitors with inhibition of the EGFR pathway through an anti-EGFR receptor antibody (cetuximab) led to the BEACON clinical trial (binimetinib, encorafenib and cetuximab). Trial patients had undergone at least one prior line of chemotherapy. The trial met all its endpoints and is now included in NCCN (National Comprehensive Cancer Network) guidelines. Herein we provide updates in treatment options for patients with BRAF V600E-mutant mCRC, focusing on the practice-changing BEACON-triplet regimen, the first chemotherapy-free combination regimen for mCRC. This combination is being explored frontline in the ANCHOR clinical trial.
Details
- Title: Subtitle
- Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
- Creators
- F. Shahjehan - Conemaugh Health SystemS. Kamatham - Wayne State UniversityC. Chandrasekharan - University of IowaP. M. Kasi - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Drugs of today (Barcelona, Spain : 1998), Vol.55(11), pp.683-693
- Publisher
- Prous Science, Sau-Thomson Reuters
- DOI
- 10.1358/dot.2019.55.11.3035584
- PMID
- 31840683
- ISSN
- 1699-3993
- eISSN
- 1699-4019
- Number of pages
- 11
- Grant note
- P50 CA174521 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 11/01/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359762202771
Metrics
10 Record Views